Alprazolam (Xanax) is a short-acting benzodiazepine (DEA Schedule IV) used for generalized anxiety disorder and panic disorder. It works by enhancing GABA activity at GABA-A receptors, producing rapid anxiolytic and sedative effects within 15–30 minutes. Common side effects include sedation, cognitive impairment, and coordination difficulties. It carries a black box warning for fatal respiratory depression when combined with opioids, and abrupt discontinuation can cause life-threatening withdrawal including seizures.
Alprazolam
Alprazolam is a short-acting benzodiazepine prescribed primarily for anxiety disorders and panic disorder. It is one of the most commonly prescribed medications in the United States and also one of the most frequently misused controlled substances. Its rapid onset makes it highly effective for acute anxiety, but also contributes to its significant potential for physical dependence and misuse. Long-term use requires careful medical supervision and monitoring.
Uses & FDA Indications
Alprazolam is FDA-approved for generalized anxiety disorder (GAD) and panic disorder, with or without agoraphobia. It is indicated for short-term symptomatic relief of anxiety and is not intended as a long-term primary treatment. Clinical guidelines generally recommend alprazolam and other benzodiazepines as adjunctive treatments or for short-term bridging therapy while longer-acting treatments (SSRIs, SNRIs, CBT) take effect.
Off-label uses include situational anxiety (such as performance anxiety or flying phobia), acute alcohol withdrawal management, chemotherapy-induced nausea (in combination), and muscle spasm, though other agents are generally preferred for these indications.
Benzodiazepines like alprazolam are effective for immediate anxiety relief but are not recommended as first-line long-term treatment for anxiety disorders. SSRIs, SNRIs, and cognitive-behavioral therapy are the preferred evidence-based long-term approaches.
How It Works
Alprazolam acts on GABA-A receptors throughout the central nervous system. GABA (gamma-aminobutyric acid) is the brain's primary inhibitory neurotransmitter. By binding to the benzodiazepine site on GABA-A receptor complexes, alprazolam enhances the effect of GABA — increasing the frequency of chloride ion channel opening. The resulting influx of negatively charged chloride ions hyperpolarizes the neuron, reducing its excitability.
This widespread CNS inhibition produces rapid anxiolytic, sedative, muscle-relaxant, and anticonvulsant effects. Alprazolam is metabolized hepatically by CYP3A4 to relatively inactive metabolites, which are then excreted renally. Its intermediate half-life (shorter than diazepam, longer than triazolam) contributes to both its clinical utility and its withdrawal potential.
Side Effects
Common
- Sedation and drowsiness
- Cognitive impairment (memory problems, reduced concentration)
- Coordination difficulties and ataxia
- Slurred speech
- Fatigue
- Depression or emotional blunting
- Paradoxical reactions — agitation, aggression, or increased anxiety (especially in elderly or children)
Serious
- Respiratory depression — significantly dangerous when combined with opioids, alcohol, or other CNS depressants; can be fatal
- Physical dependence — develops with regular use, even at therapeutic doses, within weeks to months
- Withdrawal syndrome — potentially life-threatening if discontinued abruptly (seizures, psychosis, death); medical supervision required for tapering
- Rebound anxiety — anxiety often returns more intensely after stopping alprazolam, particularly with abrupt discontinuation
- Disinhibition and behavioral dyscontrol
- Falls and fractures — especially in elderly patients
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Opioids (oxycodone, hydrocodone, fentanyl) | Synergistic CNS and respiratory depression; greatly increased overdose and death risk | Contraindicated or extreme caution — black box warning |
| Alcohol | Additive CNS depression; significantly increased risk of fatal respiratory depression | Contraindicated — never combine |
| CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) | Dramatically increased alprazolam plasma levels; risk of profound sedation | High — dose reduction required; some combinations contraindicated |
| CYP3A4 inducers (rifampin, carbamazepine, phenytoin) | Reduced alprazolam levels; loss of anxiolytic effect | Moderate — may require higher doses or alternative |
| Other benzodiazepines or sedative-hypnotics | Additive CNS depression | High — avoid concurrent use |
| Antihistamines (diphenhydramine) | Additive sedation | Moderate — avoid or use with caution |
| Fluoxetine / Fluvoxamine | CYP3A4/2D6 inhibition increases alprazolam levels moderately | Moderate — monitor for excessive sedation |
Warnings & Contraindications
BLACK BOX WARNING: Concurrent use of benzodiazepines with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve co-prescribing for patients for whom alternative treatments are inadequate. Limit doses and duration to minimum required. Monitor for signs of respiratory depression and sedation.
Contraindications: Known hypersensitivity to alprazolam or other benzodiazepines. Acute narrow-angle glaucoma. Concurrent use with certain strong CYP3A4 inhibitors (ketoconazole, itraconazole).
Dependence and withdrawal: Physical dependence can develop with regular therapeutic use. Abrupt discontinuation from alprazolam — particularly after high-dose or long-term use — can cause life-threatening withdrawal including seizures and status epilepticus. Tapering must be gradual and supervised by a medical professional.
Pregnancy Category D: Benzodiazepines cross the placenta and are excreted in breast milk. Neonatal exposure late in pregnancy can cause floppy infant syndrome, respiratory depression, and neonatal withdrawal.
Elderly patients: Older adults are particularly susceptible to sedation, cognitive impairment, and falls. Benzodiazepines are included on the Beers Criteria list of potentially inappropriate medications for older adults.
Frequently Asked Questions
Is alprazolam addictive?
Alprazolam has a significant potential for physical dependence and misuse. Physical dependence — where the body adapts to the drug and withdrawal occurs upon cessation — can develop even with therapeutic doses taken as prescribed. Psychological addiction (compulsive use despite harm) also occurs. Because of its rapid onset and short half-life, alprazolam is considered one of the higher-risk benzodiazepines for misuse within its class.
What happens if I stop taking alprazolam suddenly?
Abrupt discontinuation of alprazolam after regular use can cause a severe withdrawal syndrome including severe anxiety, insomnia, tremors, sweating, and in serious cases, seizures and psychosis. Withdrawal from alprazolam (and other short-acting benzodiazepines) can be life-threatening and must be managed with a slow taper under medical supervision.
How is alprazolam different from diazepam (Valium)?
Both are benzodiazepines working through the same mechanism, but they differ in onset speed and duration. Diazepam has a much longer half-life (20–100 hours) and active metabolites that last days, making it better for managing withdrawal and providing sustained anxiolysis. Alprazolam has a shorter half-life, faster onset, and is more potent by weight — characteristics associated with higher misuse potential.
Can alprazolam be used long-term?
Long-term use of alprazolam is generally discouraged by major psychiatric guidelines because tolerance, dependence, and cognitive impairment develop over time. For chronic anxiety or panic disorder, SSRIs, SNRIs, and psychotherapy are the evidence-based long-term treatments. When benzodiazepines are continued long-term, prescribers balance ongoing benefit against the risks of dependence, cognitive decline, and fall risk.
Need to identify an unknown pill? Use the free PillID tool.
Identify a Pill →